Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results

Bio-Rad Laboratories (NYSE:BIO) announced its quarterly earnings data on Thursday. The medical research company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.57 by ($0.06), FiscalAI reports. The firm had revenue of $693.20 million for the quarter, compared to the consensus estimate of $694.64 million. Bio-Rad Laboratories had a positive return on equity of 4.19% and a negative net margin of 26.43%.The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.90 earnings per share.

Here are the key takeaways from Bio-Rad Laboratories’ conference call:

• Q4 GAAP net income was boosted to $720M by an ~$800M valuation gain on Sartorius shares, but non‑GAAP Q4 net income slipped to $68M ($2.51) and included ~$173M of impairment charges, leaving non‑GAAP operating margin down to 12% year‑over‑year.
• Life Science momentum from the QX700 droplet digital PCR launch and the Stilla acquisition was strong — instrument sales accelerated in Q4, Stilla is now expected to be accretive by mid‑2026, and ddPCR is guided to mid‑single‑digit growth as a long‑term growth pillar.
• Gross margin was pressured in Q4 by execution‑related supply chain costs (expedited freight/overtime tied to the U.S. government shutdown) and slower procurement savings, and management says operational fixes should drive a Q1 gross‑margin step up (~100 bps) and full‑year non‑GAAP gross margin of 54.0%–54.5% in 2026.
• Process Chromatography faces near‑term headwinds — management expects ~mid‑teens decline in 2026 due to regulatory and customer demand/efficiency changes (notably in vaccines), creating lumpiness, though they see mid‑single‑digit growth longer term.
• Cash generation and capital allocation remain strong: FY2025 free cash flow was ~$375M, cash/short‑term investments ~$1.54B, 1.2M shares repurchased in 2025 (~$296M) with ~$285M still available for buybacks and continued opportunistic M&A focus.

Bio-Rad Laboratories Stock Down 10.7%

Bio-Rad Laboratories stock traded down $31.41 during mid-day trading on Friday, reaching $261.01. The stock had a trading volume of 350,825 shares, compared to its average volume of 242,429. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.94 and a current ratio of 5.44. The stock’s 50-day simple moving average is $306.69 and its 200-day simple moving average is $300.79. Bio-Rad Laboratories has a fifty-two week low of $211.43 and a fifty-two week high of $343.12. The firm has a market capitalization of $7.04 billion, a PE ratio of -10.74 and a beta of 1.18.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Wells Fargo & Company upped their price objective on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Citigroup raised their target price on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Finally, Wall Street Zen raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories has an average rating of “Hold” and a consensus price target of $358.50.

Key Headlines Impacting Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Management outlined a 2026 plan focused on margin expansion and operational improvements, and guided to 0.5%–1.5% revenue growth — a signal that management expects profitability gains even with slow top‑line growth. Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance
• Positive Sentiment: FY‑2026 revenue guidance is essentially in line with consensus (~$2.6B), reducing the risk of a down‑side surprise to revenue next year if execution on cost/efficiency initiatives holds. Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
• Neutral Sentiment: Q4 revenue rose 3.9% year‑over‑year to $693.2M — a modest beat/near‑match to street expectations that shows ongoing demand but limited acceleration. MarketBeat earnings summary and materials
• Neutral Sentiment: Management released the earnings slide deck and full call transcript — useful for investors who want details on product mix, margin initiatives, and timing of cost savings. Q4 results slide deck
• Negative Sentiment: EPS missed consensus: $2.51 reported vs. $2.57 expected, and EPS declined vs. prior‑year $2.90 — a clear near‑term profit weakness that pressured the stock. Bio-Rad Q4 Earnings Miss Estimates (Zacks)
• Negative Sentiment: Market reaction was negative: several outlets report shares tumbled after the print and commentary, reflecting investor concern over slowing growth and margin timing. Bio-Rad shares tumble as Q4 earnings miss expectations

Hedge Funds Weigh In On Bio-Rad Laboratories

Several large investors have recently modified their holdings of the business. Geneos Wealth Management Inc. grew its stake in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after buying an additional 76 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter worth approximately $47,000. State of Wyoming purchased a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth $74,000. Quarry LP lifted its position in shares of Bio-Rad Laboratories by 131.5% in the third quarter. Quarry LP now owns 287 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 163 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of Bio-Rad Laboratories by 241.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 331 shares of the medical research company’s stock worth $93,000 after acquiring an additional 234 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.